Improving treatments for infections caused by drug-resistant Klebsiella bacteria
Official title: Optimization of therapeutic mAbs to carbapenem resistant Klebsiella clone ST258
Funded at Northport VA Medical Center · NIH-11003778 · Data updated 2026-11-12
This study is working on creating better treatments using special antibodies that can fight against a tough bacteria called carbapenem-resistant Klebsiella pneumoniae, which can cause serious infections like pneumonia and sepsis, to help patients get better faster.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northport VA Medical Center NIH-funded |
| Lab location | 1 site (Northport, United States) |
| Project start | January 1, 2019 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| NIH project number | 5I01BX003741-06 |
| Project ID | NIH-11003778 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with infections caused by carbapenem-resistant Klebsiella pneumoniae, particularly those with multiple comorbidities or those in healthcare settings.
✕Less likely to help
Patients with infections caused by non-carbapenem-resistant bacteria or those who do not have access to healthcare facilities may not benefit from this research.
What this research studies
This research focuses on developing and optimizing monoclonal antibodies (mAbs) that target the capsule of carbapenem-resistant Klebsiella pneumoniae (CR-Kp), a dangerous bacteria responsible for severe infections like pneumonia and sepsis. The study aims to enhance the effectiveness of these antibodies, particularly against the diverse strains of CR-Kp that are prevalent in healthcare settings. By addressing the challenges of late diagnosis and the complexity of the bacterial capsule, the research seeks to provide a more effective treatment option for patients suffering from these infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with severe infections caused by drug-resistant bacteria, potentially reducing mortality rates.
How similar studies have gone: Other research has shown promise in developing monoclonal antibodies for similar bacterial infections, indicating that this approach has potential for success.
Where this research is happening
-
Northport VA Medical Center
Northport, United States Active
Researchers
- Principal investigator: Fries, Bettina — Northport VA Medical Center
- Study coordinator: Fries, Bettina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.